Emotional and Cognitive Aspects of PD

The Parkinson’s Disease Foundation (PDF) hosted a symposia on Parkinson’s on July 18, 2008.  The overall topic is “Mind, Mood and Body: Understanding Nonmotor Symptoms of PD.”  Here’s a link to the archived recording of the symposia:

event.netbriefings.com/event/pdf/Archives/nonmotor/register.html

The second speaker, Dr. Matthew Menza, gave a good presentation on the topic of “Emotional and Cognitive Aspects of Parkinson’s Disease.”

Even though this presentation was focused on PD, some references are made to LBD.  And, of course, there are emotional and cognitive aspects to all of the atypical parkinsonism disorders.

The most important thing I got from Dr. Menza’s presentation is that SSRIs should *not* be considered as the first line treatment in dealing with depression in PD.  A recent study showed that an old antidepressant, nortriptyline (Pamelor), performed better than Paxil, an SSRI.  Other drugs that are similar to nortriptylnie are Cymbalta and Effexor.

Of the atypical parkinsonism disorders, the only antidepressant that has been studied is Elavil (amitriptyline) in PSP.  Otherwise, I’m not aware of any studies.  You might take this recent PD research to your MD to find out if his/her recommendation would change based upon the new info.

Dr. Menza spent some amount of time on antipsychotics.  He explained that there was good data to recommend Clozaril and that in some studies Seroquel performed no better than the placebo.

He did talk about Lewy Body Dementia a couple of times, but I didn’t think his description was very good.  (Dr. Menza is a neurologist and psychiatrist.)

These are my notes from his presentation and his answers to the questions directed to him.  Of course it’s much better to watch the video yourself.

Robin


Robin’s notes from:

Emotional and Cognitive Aspects of Parkinson’s Disease
Matthew Menza, M.D., Prof. of Psychiatry and Neurology, Robert Wood Johnson Medical School

Non-motor symptoms of PD include:
* sleep disturbances, fatigue, and excessive daytime sleepiness
* depression
* drug reactions, including psychosis and impulsivity
* mild cognitive impairment to dementia

The non-motor symptoms have become the focus of research because they are so important to how patients feel day to day.

Depression:  about 40% have some.  It has a major impact on quality of life and functioning (faster progression of motor symptoms; greater decline in cognitive skills; greater decline in ability to care for self).  Depression often precedes the PD diagnosis.

Symptoms of depression include:  sadness, lack of appetite, sleep problems, lack of interest and motivation, fatigue, crying spells, etc.  Some of these symptoms are seen in PD without depression.  (6:22)

Depression is very inter-related with anxiety (worrying about things in an excessive way).  Anxiety is a common symptom in PD.

What causes depression in PD?  Probably a mix of neurochemical changes in the brain that accompany PD and the stress of living with an illness.

We encourage people to get involved in support groups.  There’s a lot of knowledge in SGs about handling day to day problems.  SG members may have common wisdom that MDs may not know about.

Try relaxation techniques to help yourself forget worries and get to sleep.  Even counting sheep.

Psycho-therapies are being modified and written expressively for those with PD.  Best to find a psychiatrist or psychologist who has experience with PD.

Exercise is a good treatment for depression.

NIH funded an 8-week trial of PD and paroxetine CR (an SSRI), nortriptyline (a tricyclic), and placebo.  This is the largest and first of placebo-controlled studies on antidepressants and PD.  This study is not yet published.  (Other studies are in the works.)  Big improvement in depression for both anti-depressants but nortriptyline was much better than paroxetine.  [paroxetine CR = Paxil CR; nortriptyline = Pamelor]  Nortriptyline affects both serotonin and norepinephrine in the brain.  Paroxetine affects only serotonin.  This study calls into question the use of SSRIs as first line treatment in PD.  Two other newer drugs that affect both serotonin and norepinephrine are Cymbalta and Effexor.  Paxil was effective for some in the study.  (23:48)

Sleep problems in PD are more common than would be expected from age alone.  50-75% of people with PD have trouble with sleep.  In their current study, sleep was the #1 predictor of quality of life (even more than motor problems).  The most common sleep problem is difficulty staying asleep (74-88% of patients).  Other problems:  poor quality sleep, difficulty falling asleep, muscle movements (PLMS and RLS; up to 15%), sleep apnea (up to 12%), RBD, morning headaches.

RBD (REM behavior disorder) is a particular concern.  PD accounts for 27% of RBD cases.  32% had injured themselves and 64% had assaulted their spouse.  Acting out dreams.  Can be a few vocalizations or something more dramatic.  People are reluctant to talk to MDs about this.  There’s a good treatment for RBD that works most of the time.

Excessive daytime sleepiness (EDS) occurs in up to 51% of PD patients.

Sleep attacks (sudden onset of sleep, usually without much warning) are associated with nearly every dopaminergic medication but especially Mirapex and Requip.  3.8% of PD patients had sudden attacks while driving.  Some still debate whether these attacks are caused by these drugs or EDS.

Sleep disturbances in PD may be related to nocturia (frequent need to urinate at night), pain, dystonia, akinesia, difficulty turning, etc.  Sleep is regulated by adrenergic, serotonergic, cholinergic, and various peptidergic symptoms which are disrupted (variably) in PD.  Depression is a major risk factor.  Dopaminergics can also worsen sleep (produce arousal and suppress REM).  (33:00)

Treatment of sleep disturbances includes:  exercise, sleep hygiene, intermittent use of sleep meds (Lunesta, Ambien, etc).  Some medications may help daytime sleepiness including Provigil, Ritalin (an older stimulant), and sometimes amantadine (Symmetrel).

Sleep hygiene:  regular sleep hours; avoid excess time in bed; regular get-up time regardless of sleep quality; avoid daytime naps (of 2 hours in length; 15 minutes is OK); use bed for sleep or sex; relaxation; physical activity; sunlight in morning; bedroom quality (noise, temperature, humidity); avoid evening stimulants; avoid large evening meals.  If you are worrying, get out of bed.  (36:34)

Two categories of unusual behaviors that sometimes accompany meds given for PD:  psychosis (hallucinations and delusions); impulse control disorders (including gambling, binge eating, buying, hypersexuality).

Psychosis is rare in untreated PD.  Can be caused by all PD meds though psychosis is somewhat more frequent with dopaminergic receptor agonists.  Biggest risk factor for developing psychosis is memory impairment.

Hallucinations (seeing something that isn’t really there) occurs in approximately 30% of PD patients.  Usually these are mild.  The problem is when hallucinations are frightening.

Delusions (belief that isn’t shared by other people in your world) occur in 3-17% of patients.  Can cause major problems and be very disruptive.  Generally later in illness when memory begins to fail.  Typically persecutory (eg, fear of being poisoned, infidelity).  Please bring these up with your MD.

There was just a large study on impulse control behaviors just discussed.  Seem to occur more frequently with Mirapex and Requip but can also occur with Sinemet.  (42:03)

In the face of these problems (psychosis or impulse control disorders), the first thing MDs do is reduce the dopamine medication.  “Motion-emotion conundrum.”  If reducing the parkinson meds doesn’t solve the problem, then MDs look to antipsychotics.  (43:08)  The first antipsychotic given is Seroquel.  If that doesn’t work, then Clozaril is tried.  Clozaril requires a weekly blood sample.  Clozaril is very effective.  (43:42)

In early PD, most develop a little of what could be described as “mild cognitive impairment.”  This is impairment of tasks requiring the frontal lobe of the brain — planning, judgment, and recall memory.  This doesn’t cause major problems.  Dopamine replacement leads to some improvement.  (44:39)

The more difficult thing is the more serious memory impairment that happens later in the disease.  Quite a few people develop this.  This is not Alzheimer’s.  This is much, much slower in development than Alzheimer’s, and generally less severe.  There are trials out there looking at the typical AD drugs (such as Exelon) in PD.  In one study, Exelon had a slightly positive response, and some with PD can take this drug.  It’s worth trying.  There is a question if Namenda will work.

Dealing with cognitive impairment includes:  household safety (and preventing wandering), reminders as to the structure of the house, day care, in-home help.

It’s important to educate yourself about psychiatric issues.  Sometimes you have to educate your physician about psychiatric issues in PD.  (46:39)

Question: Is bipolar a precursor to PD?
Answer:  I don’t think so but on the other hand certainly people with PD can develop bipolar disorder (though this would be unusual).  Bipolar disorder hits people early in life.  (48:00)

Question:  Can you elaborate on Lewy bodies?
Answer:  In Lewy body disease, there is wide distribution of Parkinson’s pathology across the brain.  This is a variant of PD where the cognitive impairment and memory impairment progresses much, much more rapidly than in normal PD.  And the individuals are much more sensitive to the adverse side effects of PD.  It’s a much more rapidly progressive illness than normal PD.  Not much is known about LBD.  It can be quite a trial.  (49:10)

Question:  What were the side effects related to nortriptyline?  (50:06)
Answer:  The newer antidepressants are better tolerated.  Surprisingly, nortriptyline (an older med) was well tolerated.  There was more constipation in the nortriptyline group.  Our lesson from the study:  don’t start with an SSRI.  (51:13)

Question:  When will a cure happen?
Answer:  Someday there will be a cure.  But what do you do now?  We need research on the problems we are having right now.  (51:56)

Question:  Can you comment on the French clozapine study?
Answer:  There have been two well-controlled Clozaril trials showing Clozaril is better than placebo for psychosis.  Weekly blood draws for six months can be a problem for some.  Some of the Seroquel trials did not show that Seroquel was any better than placebo.

Question:  Can we view panic reactions as a behavioral equivalent of a motor tremor?
Answer:  I suppose you could look at them that way.  Sometimes those with anxiety have panic attacks.  I don’t know if it’s the same neurochemically.

Question:  Depression vs. anger.  Can anger be a stimulus?
Answer:  Anger can motivate people to make changes in behavior.  If people are having a lot of anger, it’s usually based on relationships and chronic problems.  Counseling may be helpful in determining cause of anger.  Is the anger a personality change?

Question:  What determines sexual dysfunction?  Compared to what you used to do?  Frequency?
Answer:  These problems are happening in people who are older, some of whom have less interest in sex.  Autonomic dysfunction can contribute.  There are also relationship issues.  If something has dramatically changed compared to the past, then we look to some cause (medication?) for the problem.  (56:09)

Question:  If a person with PD is on bipolar meds, and needs an antidepressant, is there a conflict?  Are they more likely to become manic?  Any connection?
Answer:  This is complicated.  Lithium (a bipolar med) can sometimes not be at all well-tolerated in PD.  Med changes have to be made.  But there are some bipolar meds that those with PD can take.  Depression would be seen as a function of bipolar disorder.  In bipolar disorder, we generally try not to use antidepressants because this can worsen the mania.  But we do use them in conjunction with a mood stabilizer.  (58:10)

Question:  My husband becomes agitated and anxious.
Answer:  Agitation can be many things.  Impulsivity can be a personality change.  Is there a change in impulsivity?

Question:  How effective is Remeron for depression in PD?
Answer:  We have no idea.  Remeron is a new kind of antidepressant.  It works differently than Paxil, Prozac, that class.  Remeron tends to be very helpful with sleep.  It has a lot of antihistaminic and anticholinergic effects so it can make constipation worse.  Each antidepressant needs to be studied individually:  does this drug work in this person?

Question:  Is depression in PD hereditary?  (00:48)
Answer:  We don’t know.  We think that in non-PD depression has a hereditary component (“somewhat more likely” to develop PD).  Many people, however, with no family history develop depression, and many people with a family history of depression who never develop it.  Is there something different about PD and depression compared to PD without depression?  We don’t know but it’s a good question.

 

GI, Urological, Sexual and Other Functions – Dr. Pfeiffer’s talk

The Parkinson’s Disease Foundation (PDF) hosted a symposia on Parkinson’s on July 18, 2008.  The overall topic is “Mind, Mood and Body: Understanding Nonmotor Symptoms of PD.”  Here’s a link to the archived recording of the symposia:

event.netbriefings.com/event/pdf/Archives/nonmotor/register.html

The first speaker, Dr. Ron Pfeiffer, gave a wonderful presentation on the topic of “When Parkinson’s Interferes with Gastrointestinal, Urological, Sexual and Other Functions.”

Even though this presentation was focused on PD, lots of references are made to MSA.  And, of course, GI, urological, and other symptoms appear in all of the atypical parkinsonism disorders.

I’d heard Dr. Pfeiffer speak twice previously.  There was one new item from him:  To treat irritative urinary symptoms, he prefers the newer anticholinergics (Sanctura, Enablex, Vesicare — the first two are unlikely to cross the blood-brain barrier) compared to the older ones (Ditropan, Detrol, Levsin, Urispas, Pro-Banthine).  Tricyclics such as Tofranil can be used.

Also, he mentioned an important difference between MSA and PD:  “In PD, there can be sympathetic enervation to the heart is impaired.  (36:48)  In fact, it’s almost gone.  This doesn’t affect the functioning of the heart.  This may be useful in distinguishing PD from MSA because in MSA and in vascular parkinsonism the heart is normal.  (38:10)  This can be useful but it’s not sensitive enough.”

And I will relay his warning about Reglan:  “Don’t ever let an MD put you on Reglan, which works well but is terrible for those with PD.”  I think this caution would apply to those dealing with atypical parkinsonism disorder as well because the problem with Reglan is that it depletes dopamine.

These are my notes from his presentation and his answers to the questions directed to him.  Of course it’s much better to watch the video yourself.

Robin


Robin’s notes from:

When Parkinson’s Interferes with Gastrointestinal, Urological, Sexual and Other Functions  (he starts speaking at 1:48)
Ron Pfeiffer, M.D., Neurology, University of Tennessee Health Science Center

Non-motor features of PD:
* abnormalities of sensation
* behavioral changes
* sleep disturbances
* abnormalities of respiratory function
* autonomic dysfunction –> the focus of his presentation
* fatigue

The autonomic nervous system might be called the automatic nervous system.  It handles functions we don’t have to think about including:
* gastrointestinal –> he’ll spend most of his time here
* cardiovascular
* urological
* sexual
* thermoregulatory
* respiratory

In PD, things go wrong with the autonomic nervous system.

Gastrointestinal (starts at 5:00) dysfunction was described by James Parkinson.  GI symptoms include:
* salivary excess
* dysphagia
* nausea
* decreased frequency of bowel movements
* defecatory dysfunction
* weight loss

It had been thought that GI dysfunction was due to problems in the substantia nigra (midbrain).  Braak proposes that PD changes start in two other areas of the brain:  the olfactory center and the medulla (brain stem).  The medulla affects the vagus nerve, which controls a lot of the autonomic system.

Within the GI system, there’s another nervous system that controls the gut.  This is called the enteric nervous system.  Braak found alpha-synuclein deposition in the stomach.  So maybe PD originates not in the brain but in the stomach!  Maybe PD is transported from the stomach to the brain via the vagus nerve.  Dopamine deficiency can also be found in the enteric nervous system.

Weight loss in PD occurs in 52%.  (11:10)  May precede diagnosis.  Average weight loss is 7.2 lbs. (but 22% lose > 28 lbs!).  Reason is unclear:  reduced energy intake (but calorie intake is similar) or increased energy expenditure?

Excess saliva is experienced by 70-78% of PDers.  Saliva production is actually decreased.  Reasons saliva accumulates:  decreased swallowing frequency and efficiency, tendency for mouth to be open, stooped posture.

Treatment of excess saliva:
* anticholinergics: but these can make saliva more tenacious and viscous; systemic administration probably best avoided; sublingual atropine ophthalmic solution; can cause urinary retention and memory problems; [his slide says this but he didn’t discuss it:  glycopyrrolate avoids CNS but not peripheral AEs] * intraparotid botox: but there’s risk of pharyngeal muscle weakness
* antiparkinson medication: to improve swallowing efficiency
* gum and hard candy: very useful in a social situation
* tympanic neurectomy: he doesn’t recommend this (dubious benefit)

Dysphagia in PD occurs in 30-82%, according to questionnaires.  MBS (modified barium swallow) shows *some* abnormality in 75-97% though patients may be clinically asymptomatic.  In MBS, a barium-laced liquid, pudding, and cookie are swallowed.  MBS views mouth and throat, not esophagus.  Any phase of swallowing may be affected.

Complications of dysphagia:  (17:18)
* some degree of aspiration is present in 15-56% of those with PD.  Not necessarily full scale aspiration.  Aspiration = something getting past vocal cords.
* clinically silent aspiration present in 15-33%.  Coughing or choking when eating may be a clue.
* any abnormality increases risk of pneumonia.
[his slide says this but he didn’t discuss it:  * one particular abnormality (vallecular residue) present in 88% of patients without dysphagia.]

Oropharyngeal dysfunction diagnosed by:
* MBS
* pharyngeal manometry
* electromyography
* videomanofluroometry

Esophageal dysfunction diagnosed by:
* videofluoroscopy
* endoscopy
* esophageal manometry

Other problems that can affect the esophagus but may have nothing directly to do with PD:  (18:20)
* Zenker’s diverticulum: food collects; bad breath is common; people cough up undigested food hours after eaten; can be treated surgically
* cricopharyngeal bar: muscle that doesn’t relax when swallowing; can be treated surgically
* anterior osteophytes: arthritic changes
* achalasia: enteric nervous system is damaged and constricts down

At 19:32 there’s a good slide and discussion of how to approach diagnosis of dysphagia.

GERD can also affect swallowing.

Nausea in PD occurs in 16% of unmedicated people with PD.  (20:50)
Bloating occurs in 43% of unmedicated people
Gastroparesis (impaired emptying of stomach) may be responsible

Gastroparesis symptoms:  early satiety, sense of bloating, nausea/vomiting, weight loss

If there’s gastroparesis, alternate medication delivery routes can be sought:
* subcutaneous:  apomorphine, lisuride  (used in Europe)
* enteral (jejunal):  levodopa  (used in Europe)
* sublingual:  selegiline
* transdermal:  rotigotine  (only briefly available in US)

Prokinetic drugs can improve gastric emptying:  (23:00)
* dopamine antagonists:  domperidone works the best; this med is not available in the US; “your cagey neurologist” can probably get this medication for you from Canada.  Don’t ever let an MD put you on Reglan, which works well but is terrible for those with PD.
* serotonin 5-HT4 agonists:  Cisapride, Tegaserod, Mosapride, Prucalopride, Renzapride.  None of these is available in the US currently because of potential cardiac injury.

A gastric pacemaker can be placed to treat severe gastroparesis.  This has not been studied in those with PD.

The small intestine has not been studied in PD.  The clinical consequences of small intestine dysfunction are unclear.  Could this lead to abdominal bloating?  Could this lead to altered nutrient absorption, thereby causing weight loss?

Constipation = colonic inertia.  Decreased bowel movement frequency.  (25:12)
Defecatory dysfunction is more common than constipation, though he’s not sure everyone has found that.

The Honolulu Asian Aging Study showed that people who had less than one BM per day had:
* twice the likelihood of getting PD as compared to someone who had one BM per day, and
* four times as likely to get PD as compared to someone who had two or more BMs per day.
Unclear if this means that the presence of PD was evident years before the symptoms or if decreased bowel frequency has something to do with the etiology of PD.

Colon transit time is prolonged in PD.  Occurs in about 80% of PD patients.  (27:20)

The first step to treating constipation should always be to increase the amount of fiber and fluid one consumes.  (28:48)  Americans almost universally have a fiber-deficient diet.  If adding fiber to the diet doesn’t work, try a supplement.  Eight glasses of fluid a day need to be consumed.  Add a stool softener if that helps.  Next step is Miralax, available OTC.  Can be taken as needed or daily.  Next step is another choice of osmotic laxative.  If all else fails, enemas can be used.  It’s wise to avoid irritating laxatives for fear of damaging the enteric nervous system with prolonged used.

Medications have been looked at to speed up colon transit time:  Cisapride, NT3, Tegaserod, Prucalopride, and Lubiprostone (Amitiza).  Of these, only Amitiza is available.  The others have been withdrawn due to toxicity.  A teacher of his recommends pyridostigmine for this problem.  Surgical treatment is available:  colectomy (removal of part of the colon).

Defecatory dysfunction occurs in 66% of PD patients.  This includes increased straining, painful defecation, and incomplete emptying.  Some muscles are supposed to relax and others contract when having a BM.  In PD, this doesn’t always happen.  There can be insufficient intra-abdominal pressure.  Underlying mechanisms may be due to bradykinesia, rigidity, and dystonia of the sphincters (off-period phenomenon).  You can be tested for this but the tests (including defecography and anorectal manometry) are somewhat exotic.  There really isn’t any proven treatment for this problem.

In PD, there can be sympathetic enervation to the heart is impaired.  (36:48)  In fact, it’s almost gone.  This doesn’t affect the functioning of the heart.  This may be useful in distinguishing PD from MSA because in MSA and in vascular parkinsonism the heart is normal.  (38:10)  This can be useful but it’s not sensitive enough.

Orthostatic hypotension (drop in BP when standing) occurs in 58% of people with PD — in 20% it produces symptoms, while in 38% it produces no symptoms.  Antiparkinson meds can magnify this problem.  Lightheadedness (progressing to fainting) is the typical sensation but there are many others that people don’t realize.  (39:10)  Other symptoms include:  vision problems, impaired thinking, headache in a coathanger distribution, lower back or rear-end ache (because muscles deprived of blood), fatigue or lethargy.

Postprandial hypotension (BP drops after meals) can be triggered by carbohydrates (most likely culprit).  Sitting or standing may exacerbate.  Same symptoms as OH.  May develop within 15 minutes of eating, and may persist up to 3 hours.  In a normal person, eating a meal doesn’t cause BP to drop.  Deal with this by eating smaller meals more frequently.  Or rest/relax after eating until the problem passes.

Urinary dysfunction occurs in 27-39% of those with PD, according to newer studies.  (41:10)  Troublesome incontinence is in 15%.  Symptoms correlate with stage of disease.  Two types:  irritative (most common; consists of overactive bladder contraction) and obstructive.  Characteristics of irritative bladder are:  frequent urination, nighttime urination, urination of small amounts, urgency, and “urge” type incontinence.

To treat irritative symptoms, he prefers the newer anticholinergics (Sanctura, Enablex, Vesicare — the first two are unlikely to cross the blood-brain barrier) compared to the older ones (Ditropan, Detrol, Levsin, Urispas, Pro-Banthine).  Tricyclics such as Tofranil can be used.

Obstructive urinary symptoms include hesitancy and weak urinary stream.  May develop overflow incontinence.  Treatment is more difficult.  Intermittent catheterization is probably going to be the most effective treatment.  (44:05)

Bladder ultrasound can be a useful test to differentiate if this is an overactive or underactive bladder.

Question:  Will a colectomy have an impact on PD symptoms?  (45:45)
Answer:  I don’t think so.

Question:  Can drugs like Flomax be used in women with PD?
Answer:  I don’t think so.

Question:  Any relationship between ulcerative colitis and PD?
Answer:  I’m not aware of any.  Ulcerative colitis is an auto-immune disease.  PD is not an immune-related disease.

Question:  Is there any relationship between PD and sigmoid volvulus?
Answer:  It’s very rare and has to be treated surgically.

Question:  You mentioned injections in Europe to treat nausea and bloating. (48:22)
Answer:  Apomorphine infusions can be used to deliver meds if there’s gastroparesis but this med does not to treat gastroparesis itself.

Question:  What about diarrhea?  (51:12)
Answer:  Generally diarrhea isn’t a problem with PD per se.  Although if a person has severe constipation and gets impacted, eventually stool will liquify and go around the impaction area, and cause diarrhea.  Also, some meds can cause diarrhea.

Question:  My voice is raspy.  It feels tight around my throat.  What is this from?  (51:56)
Answer:  The most common speech problem in PD is a soft, breathy voice because people are not pushing enough air past the vocal cords or the vocal cords may not be closing tightly.  When you say “raspy,” this might be that the vocal cords are spasming.  Lee Silverman Speech Therapy has been developed for those with PD.

Question:  Should someone with PD who has frequent UTIs keep getting meds or does cranberry juice work?
Answer:  If you get an infection, you need antibiotics.  Cranberry juice may prevent UTIs.  If someone continues to get infections, a urologist may put him/her on chronic antibiotic therapy as a preventive measure.

Question:  What about sexual dysfunction?
Answer:  This is common but doesn’t get talked about much.  70% of so men have ED.  ED drugs can drop BP.  44% of men have decreased libido.  Much higher percentage of women have decreased libido.  Not much treatment for decreased libido.

Audience Member Comment:  PDers who drool give good wet kisses.

Question:  Is gall bladder inflammation related to PD?
Answer:  Nothing written about this.

Question:  Is there a portable electrical device to improve bowel function?
Answer:  I’m not aware of anything.

Question:  Bee stings caused my PD symptoms to dissipate.  Twice.  Can you speak to this?  France has been studying this.
Answer:  I’m not aware of anything in the literature about this.  Presumably this is affecting the body’s immune system.

Question:  How does Viagra affect PD or vice versa?
Answer:  Drugs like Viagra can be effective in treating ED but there can be a tendency for these drugs to cause the BP to drop.  It’s not cool to faint when you are trying to get other things done.  If you already have OH, you should probably stay away from these drugs.

 

“Driving Safety with Parkinson’s and Parkinson’s Dementia”

This will be of interest to those concerned about driving safety.

There’s a good article on the topic of driving safety in the July 2008
Parkinson’s Resource Organization newsletter. See:

Editor’s Note: Article is no longer available from source

http://www.parkinsonsresource.org/newsletters/PRO_jul08.pdf

Driving Safety with Parkinson’s and Parkinson’s Dementia
Parkinson’s Resource Organization
July 2008
(article is on pages 1 and 7)

The full article is copied below.

Robin

————————–

http://www.parkinsonsresource.org/newsletters/PRO_jul08.pdf

Driving Safety with Parkinson’s and Parkinson’s Dementia
Parkinson’s Resource Organization
July 2008

Driving is a complex activity that requires quick thinking
and reactions, as well as good perceptual abilities. For
the person with Parkinson’s and/or dementia, driving
becomes a safety issue. While he or she may not recognize
that changes in cognitive and sensory skills impair driving
abilities, you and other family members will need to be firm
in your efforts to prevent the person from driving when the
time comes.

That said, it’s important to consider the person’s feelings
and perceived loss of independence when explaining why he
or she can no longer drive. Helping the person with dementia
make the decision to stop driving — before you have to force
him or her to stop — can help maintain a positive sense of
self-esteem.

How dangerous is it?
Previous studies demonstrate that poor driving performance
increases with increased dementia severity. However, not all
people with Parkinson’s are unsafe drivers at a given point
in time. What’s more, drivers with dementia are not in more
crashes than non-demented elderly drivers, suggesting that
dementia should not be the sole justification for suspending
driving privileges. Instead, an on-the-road driving test, or
other functional test, is the best way to assess driving skills
in dementia.

Some state agencies have special drive tests to determine
how well a person sees, judges distance, and responds to
traffic. Ask the person who administers the test to explain
the results to you and the person with dementia. If your state
does not offer special testing, private assessments (generally
fee-for-service) may be available. Your local DMV, Highway
Patrol or even Senior Centers may be able to provide a list of
these programs.

How do you know when the time has come?
There are also a number of steps you can take to assess the
person’s ability to drive.

1) Look for signs of unsafe driving
Signs of unsafe driving include:
• Forgetting how to locate familiar places,
• Failing to observe traffic signs,
• Making slow or poor decisions in traffic,
• Driving at an inappropriate speed,
• Becoming angry or confused while driving.
Keep a written record of your observations to share with the
person, family members and health care professionals.

2) Learn about your state’s driving regulations
In some states, such as California, the physician must
report a diagnosis of Parkinson’s to the health department,
which then reports it to the department of motor vehicles.
That agency then may revoke the person’s license. Check
with your local DMV for information on driving regulations in your
state.

Tips to limit driving
Once it’s clear the person with dementia can no longer drive safely,
you’ll need to get him or her out from behind the wheel as soon as
possible. If possible, involve the person with dementia in the decision
to stop driving. Explain your concerns about his or her unsafe driving,
giving specific examples, and ask the person to voluntarily stop driving.
Assure the person that a ride will be available if he or she needs to go
somewhere.

Other tips to discourage driving include:

• Transition driving responsibilities to others. Tell the person you can
drive, arrange for someone else to drive, or arrange a taxi service or
special transportation services for older adults.

• Have prescription medicines, groceries or meals delivered.

• Solicit the support of others. Ask your physician to advise the person
with dementia not to drive. Involving your physician in a family
conference on driving is probably more effective than trying by
yourself to persuade the person not to drive. Ask the physician to
write a letter stating that the person with Parkinson’s must not drive.
Or ask the physician to write a prescription that says, “No driving.”
You can then use the letter or prescription to tell your family member
what’s been decided.

• Experiment with ways to distract the person from driving. Mention
that someone else should drive because you’re taking a new route,
because driving conditions are dangerous, or because he or she is
tired and needs to rest. Tell the person he or she deserves a chance
to sit back and enjoy the scenery. You may also want to arrange for
another person to sit in the back seat to distract the person while
someone else drives. If the disease is in an advanced stage, or there
is a history of anger and aggressiveness, it’s best not to drive alone
with the person.

In the later stages, when the person is no longer able to make decisions,
substitute his or her driver’s license with a photo identification card.
Take no chances. Don’t assume that taking away a driver’s license will
discourage driving. The person may not remember that he or she no
longer has a license to drive or even that he or she needs a license.

What if the person won’t stop?
If the person insists on driving, take these steps as a last resort:

• Control access to the car keys. Designate one person who will do all
the driving and give that individual exclusive access to the car keys.

• Disable the car. Remove the distributor cap or the battery or starter
wire. Ask a mechanic to install a “kill wire” that will prevent the car
>from starting unless the switch is thrown. Or give the person a set of
keys that looks like his or her old set, but that don’t work to start the
car.

• Consider selling the car. By selling the car, you may be able to save
enough in insurance premiums, gas and oil, and maintenance costs to
pay for public transportation, including taxicab rides.

In some states, it might be best to alert the department of motor
vehicles. Write a letter directly to the authority and express your
concerns, or request that the person’s license be revoked. The letter
should state that “(the person’s full name) is a hazard on the road,”
and offer the reason (Parkinson’s disease or Dementia). The state may
require a statement form your physician that certifies the person is no
longer able to drive.

Explanation of statistics in “Clinical outcomes” paper

Recently I had posted about this O’Sullivan “Clinical outcomes” paper.  And I had asked if anyone knew statistics and could understand what “older age of onset” means (the abstract indicates in MSA “older age of onset” is a factor “predicting shorter disease duration until death”) and what “early autonomic dysfunction” means (in MSA “early autonomic dysfunction” is a factor predicting shorter survival).

Well….local support group member Ted is a biostatistician!  He has answered these two questions in addition to providing a useful (and short) summary and some interesting comments about what is statistically significant.  Here’s Ted’s email below.  It’s just in time for the support group meeting tomorrow:  I know some of you MSA caregivers are really interested in this article!  Thanks Ted!

Robin

—————————-

From Ted, local Brain Support Network group member

This is a complicated paper, so I’ll try just to summarize the parts I think are interesting, without adding very many thoughts of my own.

First, the very short version: MSA tends to start at a younger age than PSP.  Survival after getting the disease averages about 8 years for both diseases.

If you have PSP, you will tend to live longer if your early symptoms are more like typical Parkinson’s, if you are younger when you get the disease (though the difference isn’t large), if you are female, or if it is a comparatively long time before you hit your first “clinical milestone”, a list of bad things that happen as the disease progresses (I have a list below).

If you have MSA, you will tend to live longer if you are admitted to residential care at some point, if you do not have early autonomic dysfunction (various symptoms related to urination, digestion, sweating, blood pressure, and sexual function, within the first two years after onset; list below), if you are younger when you get the disease (again, not a big difference), if you are male (but this is a little complicated, as I explain below), and if it is a comparatively long time before you reach your first clinical milestone.

For both diseases, the degree of response to L-dopa does not appear to be associated with survival, at least in this study.

In this paper, the diagnosis of PSP or MSA is based on autopsy results.  The authors note that the accuracy of diagnosis during the patients’ lifetimes was less than 100%, and that PSP and MSA are often hard to distinguish during the patient’s lifetime.   All the conclusions presented were based on a set of 110 PSP patients and 83 MSA patients who had sought treatment and permitted autopsies at the Queen’s Square Brain Bank for Neurological Disorders.  This group of patients may not be exactly comparable to our own group of family members with PSP and MSA.

Now the less short version, in answer to your two questions:

Older age of onset:  First, “age of onset” means the age at which the first symptom attributable to PSP or MSA appeared in the patient’s medical record.  This is usually earlier than age at diagnosis (by 3-4 years on average; table 1).  “Older age of onset” does not refer to any specific cutoff age, but instead to the authors’ finding that patients who are older at onset tend not to live as long as patients who are younger at onset.  The “hazard ratio” for age of onset increases at 5% per year for both MSA and PSP (table 2).  The “hazard” is the rate at which patients die, so it would be measured in units like 10 deaths per year per 100 patients.   So, for example, patients with age of onset 64 would have a hazard approximately 20% higher (hazard ratio 1.2) than that of otherwise comparable patients with an age of onset of 60 (4 years younger at onset times 5% per year).

This is a small effect compared to some of the others shown in the table.  As an example, for PSP patients, male gender has a hazard ratio of 1.7 (meaning men have a 70% higher hazard than comparable women), which is equivalent to about an 11-year age difference at onset (the actual calculation is somewhat more complicated than just multiplying number of years times 5%).  So for PSP patients, a male with onset at 60 would have about the same hazard as an otherwise similar female with onset at 71.  Age isn’t in the same league as the big hazard ratios in the table, such as early autonomic dysfunction for MSA patients (hazard ratio 6.0).   I don’t think it’s clear from the paper how much of the age effect is due to differences in the progression of the disease versus just the increased hazard you would see in any comparison of older people versus younger.

Early autonomic dysfunction:  The autonomic nervous system regulates bodily functions like heart rate, respiration, digestion, salivation, urination, and sexual arousal.   For the purposes of the paper, autonomic dysfunction was defined to mean either an abnormal autonomic function test result, or (and I think this was what was used for the vast majority of cases) having two or more of the following set of symptoms, as reported by the patient:

  1. Frequent or urgent need to urinate, or “nocturia without hesitancy”, which sounds like it might mean either bedwetting or urgently needing to get up during the night to urinate; I’m not sure of the exact medical usage;
  2. Chronic constipation;
  3. Postural hypotension, presenting either as a complaint from the patient or just from observing a sufficient difference between sitting and standing blood pressure in the doctor’s office;
  4. Sweating abnormalities; and
  5. Erectile dysfunction.

Autonomic dysfunction was classified as early if it appeared within 2 years of onset (as defined above, first attributable symptom in the medical record).  The presence of erectile dysfunction on the list is a complicating factor, because it is a symptom that only men can experience, which means it is easier for a male patient to be classified as having early autonomic dysfunction than a female patient.  The authors mention this, and note that, as one would expect, a higher proportion of male patients had early autonomic dysfunction.  I’ll say a bit more about this later.

Finally, some unsolicited bonus commentary:

If you read the paper yourself, the word “significant”, or “statistically significant”  is used in a technical sense different from the everyday meaning.  A statistically significant effect is one for which the evidence is strong.  The effect itself may be rather weak (or it may not be).  So, for example, in table 2 the effect of age of onset is statistically significant, but it doesn’t have a very large effect on the hazard ratio compared with, say, the RS phenotype for PSP.

OK, then going over table 2, the biggest effect for PSP seems to be the RS phenotype.  This means that time to survival is shorter for patients whose main symptoms during the first two years are falls, cognitive dysfunction, supranuclear gaze palsy, abnormal saccadic (quick) eye movements, and postural instability.  PSP-P patients, whose first two years are more along the lines of typical Parkinson’s, with slow movement, tremor, some response to L-dopa, asymmetric onset and limb stiffness, tend to survive longer.  The hazard ratio is 2.37.   There were some patients for whom it was not clear which group they fell into, and they were excluded from the analysis.  Male gender is associated with shorter survival (hazard ratio 1.7), as is older age of onset, but for age it’s not a big difference.  Finally, patients who reach their first clinical milestone later tend to survive longer.  This is another per-year effect, with each year of delay for the first milestone reducing hazard by 20%.  On average, PSP patients’ time to first milestone varies by two or three years (bottom rows of table 3, showing a standard deviation of 2.7 years for PSP), so at 20% per year this is a pretty big effect.

For MSA, the big effects, which are really big, are early autonomic dysfunction (hazard ratio 6.0), and female gender (hazard ratio 3.0).  Both of these shorten survival, and I think they have to be viewed as a unit because of the erectile dysfunction symptom, which makes it easier for men to be classified as having early autonomic dysfunction.  It seems to me the high estimated hazard ratio for the female group may partly be explained as a “penalty” the female group pays for the greater proportion of undiagnosed early autonomic dysfunction in that group (this is my opinion, not the authors’, and I could be wrong).  Again for MSA patients, age of onset and interval to first milestone show up, with similar results.  Finally, not being admitted to residential care has an estimated hazard ratio of 2.8, so (perhaps surprisingly) residential care seems to increase survival for MSA.

The clinical milestones are a list of seven bad things that may happen to patients between disease onset and death: (1) frequent falls (2/year or more); (2) dependency on a wheelchair; (3) unintelligible speech; (4) severe dysphagia (difficulty swallowing); (5) use of a urinary catheter; (6) cognitive impairment; and (7) entering residential care.  Most patients experience at least a few of these (figure 2), but very few experience all seven.  Table 3 is a big summary of roughly when each milestone tends to occur (among patients that experience it), and a comparison of frequency of milestones between the disease groups.  Figure 4 plots the average times at which milestones occur, relative to the disease course, for Parkinson’s, PSP, and MSA.  The figure also shows time of diagnosis.  I’m a little dismayed to see how MSA patients seem to have a pileup of milestones at the end of life (although again, most patients don’t experience all milestones, and the times shown are the average for patients that do experience it).   I like the way the figure displays the average age of onset and duration for the three diseases.

Here’s the figure four of the O’Sullivan paper:

O’Sullivan et al, Fig. 4

Well, I think that’s all I have to say.  I hope it’s not too incomprehensible.  Please feel free to distribute this, or parts of it, to the group.

 

Ted

Back rash

This was posted on 1/6/06 by Pauline:

ed,

It was not discovered what made the raging rash on Greg’s back, but I believe it was from severe sweating against the wheelchair back which is Naugahyde. We were in Florida at the time of the rash showing up.

Doctor prescribed the benedryl-like drug to allow Greg to sleep at night. The doctor had me wash and rinse his back, mix half & half white vinegar and warm water and rinse again, pat dry thoroughly and apply a very thin layer of Triamcinolone Acetonide Ointment USP, 0.1% as prescribed. I think that the doctor prescribed the vinegar/water solution to dissolve any possibility of soap or other residue and cause a drying effect on the nearly blistered skin.

We were lucky Greg only had it on his back. In the past, this same ointment has been prescribed for me by a dermatologist for itchy, scaly patches on my lower leg and it cleared it up completely. That doctor told me if I could see the ointment on my skin I had used too much, so it is a very thin layer that is used.

Pauline

————————————————————————————————-

I received the following via email today (4/13/08):

I would like to copy an email I sent to Pauline in Maine in case you can answer my question.

Here goes:
Hello Pauline in Maine,
I was wondering if you ever discovered the cause of the back rash. My husband has complained of this off and on since his hip replacement surgery a few years ago. At first I thought it was chemicals used to launder the sheets in the hospital coupled with the heat he generated by laying on them for so long. It’s been a few years now, since his surgeries, and he still complains. I’ve tried changing laundry soaps, given him benedryl, nothing seems to make it go away. Also, his symptoms seemed to appear soon after the surgery as well. I must add that prior to his surgeries (double hip replacement), he was also diagnosed with high blood pressure and started taking toprol. Several months later vytorin, plavix, cozaar and norvask were added.
Do you think there is any connection to this? Do you have any suggestions on how this can be treated?

Thank you.

————————————————————————————————-

I’m posting this here because others have had experiences with rashes and can be helpful.

Many with PD and PD-related disorders get seborrheic dermatitis (a form of eczema). A dermatologist should be able to look at the rash and tell what sort of rash it is.

If it’s seborrheic dermatitis, dermatologists often prescribe hydrocortisone (some strengths are available OTC), Elidel, and Protopic. A relatively new product is Xolegel.

For my father, for seborrheic dermatitis on his arms and chest, we used Elidel, and it worked very well.